Novo Nordisk chooses China for largest foreign investment
This article was originally published in Scrip
Novo Nordiskis making its single largest investment ever outside Denmark in a Chinese facility for the manufacture of insulin products. The firm will spend close to $400 million on a new formulation and filling plant at its existing site in the northeastern city of Tianjin.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.